The pamoate salts of N-(cyclopropylmethyl)-7,8-dihydro-14-hydroxynormorphinone and N-allyl-7,8-dihydro-14-hydroxynormorphinone, in oil suspension, are injectable, long-acting forms of these narcotic antagonists.
Novel N-sec-alkyl derivatives of norcodeine and normorphine wherein the sec-alkyl group contains either four or five carbon atoms. Specifically included are those derivatives of norcodeine and normorphine wherein the sec-alkyl group is 2-butyl, 3-pentyl, .alpha.-methylallyl and .alpha.-methylcyclopropylmethyl. The normorphine derivatives have strong agonist potency combined with strong antagonist qualities and indicated low addiction potential. The norcodeine analogs are useful as intermediates in preparing the corresponding normorphine compounds.
Novel N-sec-alkyl derivatives of norcodeine and normorphine wherein the sec-alkyl group contains either four or five carbon atoms. Specifically included are those derivatives of norcodeine and normorphine wherein the sec-alkyl group is 2-butyl, 3-pentyl, .alpha.-methylallyl and .alpha.-methylcyclopropylmethyl. The normorphine derivatives having strong agonist potency combined with strong antagonist qualities and indicated low addiction potential. The norcodeine analogs are useful as intermediates in preparing the corresponding normorphine compounds.
This invention concerns a method for decreasing both the oral and parenteral abuse potential of strong analgetic agents such as oxycodone, propoxyphene and pentazocine by combining an analgesic dose of the analgetic agents with naloxone in specific, relatively narrow ranges. Oxycodone-naloxone compositions having a ratio of 2.5-5:1 parts by weight and pentazocine-naloxone compositions having a ratio of 16-50:1 parts by weight are preferred.
The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation or olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
